

10 May 2017  
ASX Code: MXC

## CEO Appointment

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

- Mr Roby Zomer, a founder and currently an Executive Director and CTO, has been promoted by the Board to CEO of MGC Pharmaceuticals
- Strengthens the management team for delivery on core business goals, bringing strong corporate and operational experience to the role from the biotech and agritech sectors
- Previously founder and CEO of Israeli renewable energy company, Green City Urban Recycling, with major shareholder the Israeli industrial giant RAFEAL
- As CEO, Mr Zomer will be responsible for the Company's global operations as it emerges as a leading medical cannabis pharmaceutical company
- Mr Zomer will continue working closely with Managing Director, Mr Nativ Segev who will be responsible for new business and industry strategy

**MGC Pharmaceuticals Ltd (ASX: MXC or "the Company")** is pleased to advise that current Executive Director and Chief Technical Officer (CTO), Mr Roby Zomer has been appointed as Chief Executive Officer (CEO).

Mr Zomer is a founder of MGC Pharmaceuticals Ltd, and brings over nine years of strong corporate and operational experience to the role. Leveraging his experience and knowledge within the field of eco sustainable projects, Mr Zomer has a proven track record of international success within the biotech and agritech sectors.

He was founder and CEO of Green City Urban Recycling Ltd, an Israeli renewable energy company with strong social and environmental values. As part of Mr Zomer's role, he was a representative of the biofuels industry to the Government of Israel, giving him an extensive background in international and government relations as well as emerging industries. At Green City he led the 48% sale of the company to the high profile global defense systems company, RAFEAL (inventor of the Iron Dome, a mobile all-weather air defense system). He was also responsible for establishing energy projects in Brazil, Italy, Montenegro and Jordan.

Mr Zomer joined MGC Pharmaceuticals in 2015 and has been instrumental in developing the Company's research and development operations. As CTO, Mr Zomer played a critical role in progressing its epilepsy and dermatological skin care research programs. This work has led to the Company's clinical study to evaluate its medical cannabis product as a viable treatment for epilepsy among children and adolescents at University Children's Hospital Ljubljana, one of the largest hospitals in central Europe.

Additionally, Mr Zomer's background in engineering brings a wealth of scientific knowledge, contacts and operational experience. This knowledge and operational efficiency contributed to the expedited commencement of MGC Pharmaceuticals' cannabinoid extraction operations in its newly completed European extraction facilities.

As CEO, Mr Zomer will be responsible for the Company's global operations as it emerges as a leading biopharmaceutical company in the medical cannabis sector. Mr Zomer will continue to report to MGC Pharmaceuticals Managing Director, Mr Nativ Segev, who will be responsible for the Company's new business and industry strategy.

### Nativ Segev, Co-founder and Managing Director, MGC Pharmaceuticals commented:

"I am delighted to announce the appointment of my colleague Roby Zomer as CEO of MGC Pharmaceuticals. Roby has been a driving force within MGC Pharmaceuticals helping to achieve our vision of making safe and effective medicinal cannabis products available across key geographies. His passion for the sector, along with his hard work and commitment will continue to drive forward the development and growth of our Company now and into the future."

- Ends -

---

#### For further information, please contact:

##### Media Enquiries

Ben Grubb

Account Director

Media and Capital Partners

+61 414 197 508

[ben.grubb@mcpartners.com.au](mailto:ben.grubb@mcpartners.com.au)

##### MGC Pharmaceuticals Ltd

Brett Mitchell

Executive Chairman

+61 8 9389 2000

[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

### About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based specialist medical cannabis company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company's founders were key figures in the Israeli medical cannabis industry and the core business strategy is to develop and supply high quality Cannabinoids based pharmaceuticals products for the growing demand the medical markets in Europe, North America and Australasia.

Follow us through our social media channels   